Introduction
Infectious complications remain a substantial cause of morbidity and mortality in patients undergoing therapy for acute myeloid leukemia (AML). [1] [2] [3] It has been estimated that children with AML experience at least three infectious episodes during intensive therapy. 2 In the past, infection-related mortality has been reported to be as high as 31%. 1, 2, 4 Whereas Gram-positive bacteria are the most common isolate from the bloodstream, Gram-negative bacteria and fungal pathogens are associated with increased risk for mortality. 2 Studies over the past 30 years have identified a set of clinical risk factors for serious infection during leukemia therapy. These include neutropenia, indwelling central venous catheters, and therapeutic regimens that induce severe mucosal damage (eg, high-dose cytarabine). 2, 5 However, it is probable that additional factors contribute to the differences in clinical outcomes in children receiving comparable intensive therapy, the single most important risk factor for infection in the immunocompromised child.
In the process of generating a sequence of the human genome, a remarkable set of tools has emerged, the annotation of common genetic variants. 6 The catalogue of annotated variants across the genome has already identified host genetic factors that influence clinical outcomes. Even though it is estimated that there are more than 6 million single nucleotide polymorphisms (SNPs) with a minor allele frequency of greater than 5-10%, 6 only a small subset probably has functional implications, namely an alteration in protein structure or gene expression. 7 Until recently, the choice of genetic variants for study was limited, but with intensive investigation into key genes in well-defined pathways, such as innate immune genes, it is possible to examine a set of variants in which there is substantially strong in vitro and prior association data. 8 Common, well-defined candidate genetic variants in innate immune pathways critical for host defense have been identified as risk factors for susceptibility and/or outcome to pathogens, such as malaria, the human immunodeficiency virus, or Candida infection in leukemia patients. [9] [10] [11] Moreover, common genetic variants in proinflammatory cytokine genes, such as tumor necrosis factor-alpha (TNF), interleukins 6 and 8 (IL6 and IL8) contribute to interindividual differences in circulating levels of these cytokines. 12, 13 The reported findings provide correlative data in support of genetic variation as a risk factor for clinical outcome. It is likely that small changes in the expression or function of these key components can perturb the delicate balance between circulating cytokines and thus, modulate the inflammatory response, which in turn, could impact susceptibility to infectious complications. 12, 14, 15 Others have reported that common polymorphisms in the genes of the lysosomal enzyme myeloperoxidase (MPO) and the human chitinolytic enzyme chitotriosidase (CHIT) have been associated with bacterial infection in marrow transplantation and in a region endemic for a filarial parasite. 16, 17 Similarly, common variants in the low-affinity Fc receptor (FCGR2A), and the toll-like receptors 2 and 4 (TLR2 and TLR4) have been associated with immunological complications as well as bacterial and fungal infections. [18] [19] [20] [21] We have chosen to study common genetic variants in genes of innate immunity, which might influence the risk for infectious complications in patients undergoing treatment for AML. The rationale is that genetic variants resulting in subtle changes in healthy, normal individuals could assume greater significance in immunocompromised patients, such as children undergoing therapy for AML. 8 We therefore conducted an exploratory study with variants from eight genes for which there was excellent prior data performed to determine if any of these common variants influence the risk for serious infection during therapy for pediatric AML.
Materials and methods
The study group consisted of children with AML treated on clinical trial AML-BFM 93 in whom samples were available. 22 Clinical data were collected from chart review at each center. The study protocol was approved by the local ethics committee.
Briefly, the treatment protocol was as follows. All patients received induction therapy with either daunorubicin or idarubicin in combination with cytarabine and etoposide. After induction, patients were stratified according to risk groups; highrisk patients received both HAM (high-dose cytarabine and mitoxantrone) and consolidation (6-thioguanine, prednisolone, vincristine, cytarabine, and cyclophosphamide), whereas standard risk patients received consolidation without HAM. 22 All patients received intensification with HAE (high-dose cytarabine and etoposide), cranial irradiation and maintenance therapy for a total of 18 months of therapy. 22 A detailed analysis of the infectious complications of this study population has been reported previously. 2 Infectious events were categorized according to the presence of neutropenia (absolute neutrophil count p500/ml), microbiological or clinical documentation of infection or fever without an identifiable source (FUO).
Genomic DNA was extracted from cryopreserved lymphocyte pellets by a salt precipitation-extraction method (Gentra Systems); a minority of extractions was performed with blood smears using a standard phenol-chloroform extraction method. 25 Each of the polymorphisms was chosen because of prior data on its functional importance and a minor allele frequency greater than 5%. 12, 13, [16] [17] [18] [19] [20] [21] 26, 27 In a subset of patients, serum levels of IL6 were assessed using a commercially available enzyme immunoassay (ELISA) (R&D Systems, Minneapolis, MN, USA). Serum was obtained at the time of diagnosis of AML and/or at the time of admission of febrile neutropenia, as reported previously in detail. 23 Children with fever for longer than 24 h prior to admission of febrile neutropenia were excluded.
Differences in proportions (using Fisher's exact test), odds ratios (ORs) and their exact 95% confidence interval (CI) were calculated with the software SAS System (Version 8.2 for Windows). In this exploratory analysis, a value for Po0.05 (two-tailed) was considered to be significant. 19 The primary analysis was conducted for each gene separately and included consideration for false-positive findings using the method described by Wacholder et al. 28 This robust tool (false-positive rate probability (FPRP)) was chosen for analysis in genes in which there was a high prior probability that the finding is noteworthy. 29 Cumulative incidence functions were constructed by the method of Kalbfleisch and Prentice and were compared with Gray's test. 30, 31 The Wilcoxon rank sum test was used for the analyis of IL6 levels of the individual groups categorized by the type of infection established at the time of admission. 23 
Results
Our analysis included 168 North European Caucasian pediatric patients treated on clinical trial AML-BFM-93 (Table 1) . Seven patients underwent allogeneic stem cell transplantation, which was performed after consolidation therapy. The clinical characteristics of the study population did not differ from the characteristics of the previously reported subjects drawn from clinical trial AML-BFM 93. 22 Detailed hospital chart review identified 508 infectious episodes, which resulted in roughly three episodes per patient. Only three patients escaped significant infectious complication, whereas seven patients died due to infection-related complications. In all, 110 patients had at least one microbiologically documented infection (68 patients with one, 23 with two, 16 with three, two with four, and one patient with six episodes). Gram-positive bacteria were isolated in the bloodstream of 84 children, whereas Gram-negative bacteria were recovered from the bloodstream of 24 patients. More than one episode of bacteremia occurred in 28 children, specifically, 26 with Grampositive bacteremia and two with Gram-negative bacteremia. The predominant Gram-positive pathogens isolated in the bloodstream were staphylococci and streptococci (n ¼ 54 and n ¼ 46, respectively), whereas Klebsiella spp. (n ¼ 6), Escherichia coli (n ¼ 6) and Pseudomonas aeruginosa (n ¼ 5) accounted for most of the Gram-negative isolates. Standard risk and highrisk patients were comparable regarding infectious complications with the exception of a higher incidence of Gram-positive bacteremia in the high-risk group (18/53 in the standard risk group (34.0%) vs 66/115 in the high-risk group (57.4%); P ¼ 0.005).
Genotype frequencies were analyzed using 3 Â 2 contingency tables according to the presence or absence of infectious outcomes (Table 2 ). An analysis of the distribution of genotypes for each genetic variant conformed to Hardy-Weinberg equilibrium. The distribution of these variants was comparable to the distribution of the same variants in blood donors from Germany (data not shown).
Our analysis revealed that genetic variants in two distinct genes, both with high priors for inclusion, IL6 and CHIT, were associated with documented bacteremia in children undergoing therapy for AML. We observed an association between microbiologically documented infections and the IL6 promoter variant at À174, known to alter expression of IL6: the risk for infection was significantly higher in patients heterozygous or homozygous for G-174 of IL6 promoter: 18 of 29 homozygotes for the allele G (62.1%) and 67 of 94 heterozygotes (71.3%), but (21) 8 (24) 4 (14) 18 (24) 2 (15) 20 (22) 10 (18) 12 (26) 2 (29) 20 (21) TNF ( Subcolumns on the left side show the number (%) of patients who experienced a certain infectious complication, whereas subcolumns on the right side represent the patients without a certain infectious complication. Not all samples amplified for certain genes. Patients who experienced both Gram-negative and Gram-positive bacteremia during intensive treatment for AML (n ¼ 12) were counted in both groups. P-values are an explorative measure for evidence of an association based on comparison of patients with AML and a specific infectious complication and control patients with AML without a specific infectious complication, using Fisher's exact test. No individuals homozygous for w1 were observed. OR not defined) ). The analysis for allele frequencies was also significant (data not shown). Similar results were obtained when analyzing the standard risk and the high-risk group separately, but it is not surprising that the analysis was not significant because of the small numbers: (9/37 (24.3%) vs 0/13 (0%) for standard risk patients P ¼ 0.05 (OR not defined), and 13/86 (15.1%) vs 0/12 (0%) for high risk; P ¼ 0.15). In contrast, an analysis of the cumulative incidence revealed a significant difference between patients heterozygous or homozygous for G-174 of IL6 promoter and patients homozygous for the C allele (P ¼ 0.026). We did not observe an association between the IL6 promoter genotype and the serum level of IL6 measured at the time of diagnosis of AML or at the time of admission for neutropenia and fever due to microbiologically documented infection, Gram-positive or Gram-negative bacteremia or due to FUO (Table 3) .
Polymorphisms in infections in childhood AML
T Lehrnbecher et al0 (0) 0 (0) 1 (1) 0 (0) 1 (1) 1 (1) 0 (0) 0 (0) 0 (0) IL6 (À174) GG
The second genetic variant to be identified in our analysis is the H allele in CHIT, which is a 24 bp insertion in the coding region. The risk of bacteremia with Gram-negative organisms was significantly higher in patients with the H allele of CHIT: one of eight homozygotes for H (12.5%) and 12 of 48 heterozygotes (25%), but only 11 of 112 homozygotes for the allele T (9.8%) suffered from Gram-negative bacteremia (2 Â 2 contingency table: HH þ HT (13/56; 23.2%) vs TT (11/112; 9.8%); P ¼ 0.033 (OR 2.78; 95% CI 1.05-7.40)). Similar results were obtained for the analysis of the cumulative incidence (HH þ HT vs TT; P ¼ 0.015).
We did not observe significant associations in the analysis of common variants in MPO, FCGR2A, TNF, IL8, TLR2, and TLR4 and the major infectious end points of study in children with AML. In particular, there was no overrepresentation of any of the variant genotypes in patients with invasive fungal infection, in patients with a severe clinical course (eg, hypotension, respiratory failure) or in patients with fatal outcome due to an infectious complication (data not shown).
Further analysis of risk factors for Gram-negative bacteremia in our retrospective cohort did not reveal any discernible difference with respect to gender, age, Down's syndrome, FAB Table 3 Children with AML: IL6 C-174G promoter polymorphism and IL6 serum level measured at the time of diagnosis of AML and at the time admitted to the hospital for febrile neutropenia due to microbiologically documented infection, Gram-negative and Gram-positive bacteremia or due to fever of unknown origin (FUO) No statistically significant difference of IL6 levels was observed among patients with different IL6C-174G promoter genotypes. Table 4 Comparison of episodes of bacteremia with Gram-negative organisms with infectious complications other than Gram-negative bacteremia in pediatric patients with acute myeloid leukemia 
T Lehrnbecher et al classification, and risk stratification (data not shown). Auxiliary analyses of clinical parameters were also not associated with the candidate, functional variants chosen in this study; specifically, the analysis examined the depth or duration of neutropenia, the presence of a central venous line, prophylactic use of thrimethoprim-sulfamethoxazole, the use of nonabsorbable antibiotics, or the frequency of prior chemotherapy with highdose cytarabine (HAM and HAE) ( Table 4) .
Discussion
In our analysis, we have shown that genetic variants in two genes, IL6 and CHIT, are associated with Gram-negative bacteremia in children undergoing therapy for AML. Our findings for the promoter variant of IL6 are consistent with prior studies that demonstrated a contribution of the same promoter variant in IL6 to bacterial sepsis in newborns. 14 Interestingly, both newborns and children undergoing intensive chemotherapy for acute leukemia are considered immunosuppressed and often suffer infection with opportunistic and serious bacterial infections. 2, 14 The observed association between a functional variant of CHIT and bacterial infection is striking and suggests that the CHIT gene could have more pleotropic effects in innate immunity than previously appreciated.
Our observation that the G allele of IL6 variant at À174 could be associated with an increased risk for significant bacterial infection, specifically with Gram-negative pathogens, is consistent with prior published data that the GG genotype of IL6 is associated with bacterial sepsis in preterm infants.
14 Since the C allele has been associated with decreased transcription, it is plausible that alteration of the IL6 response could perturb the balance of the downstream cascade, particularly during the acute response to Gram-negative infection. 13 We did not observe an association between the IL6 promoter genotype and the serum level of IL6 measured. This finding corroborates other studies and is not surprising for the following reasons. 23, 32 Measured IL6 levels are highly variable (even over minutes), and more so in the presence of inflammatory stimuli. Thus, a single point measurement is insufficient to assess a dynamic change, perhaps associated with underlying genetic variation. The effects of the IL6 promoter alleles have been investigated in vitro, 12,13 and do not fully account for the factors influencing levels in children with AML and chemotherapy-induced neutropenia. The increase of the concentration of IL6 after endotoxin challenge, which is up to several thousand-fold, probably overrides any genetically controlled fine-tuning effect. The fact that the infection risk was only affected by genetic variants of IL6, but not of other molecules such as TNF or IL8 might be explained with the unique function of each molecule of innate immunity in the complex network of inflammatory regulators, although the molecules exhibit broad overlapping effects. An important contribution of IL6 variants in leukemia seems unlikely, since the distribution of IL6 genotypes was similar to that of healthy individuals. However, we recognize that the IL6 promoter polymorphism could be in linkage disequilibrium with another, yet unidentified, variant, which, in turn could be 'causal'.
The observation that the H allele of CHIT was associated with a higher risk for Gram-negative infection is plausible, especially since the H allele is characterized by a 24-base pair duplication in exon 10 that activates a cryptic 3 0 splice site, generating a mRNA with an inframe deletion of 87 nucleotides. 26 The frequency of the minor CHIT variant, H, is unexpectedly high in many studied populations; its biological effect is to disrupt protein production. 26 Although the human CHIT gene has been shown to be important as an innate immune gene against chitin containing pathogens, such as yeast or nematodes, its role in bacterial host defense mechanisms is under active investigation, particularly in relation to first-line innate response to pathogens, such as bacteria.
We recognize that a limitation of our study is the sample size and have chosen to analyze the data individually by gene, but using a false-positive discovery tool, which provides an estimation of the degree of noteworthiness. 28, 29 Accordingly, we present our data as a first step and plan to seek replication in subsequent studies. We also recognize that an additional causal variant, in linkage disequilibrium could contribute to the observed effect. Thus, it will be important to examine haplotype structures of these and any other genes in follow-up studies. 33, 34 In conclusion, we report that functionally important variant alleles in both IL6 and CHIT could influence susceptibility to infections with Gram-negative bacteria in children undergoing therapy for AML. Our analysis was restricted to Caucasian children undergoing AML therapy in Germany. Thus, application to other study populations will need to take into account differences in underlying population structure. Still, for these alleles, it is unlikely that allele frequencies will vary significantly in subjects of North European ancestry. 35 If our findings are confirmed in follow-up studies, these data, and perhaps additional common genetic variants, could be considered in the decision to institute antibacterial prophylaxis in children at especially high risk for Gram-negative bacteremia. These observations might also lead to new strategies designed to intervene at one or more vulnerable points in host response to infection, particularly in immunocompromised children. 36 The latter are especially vulnerable because the detrimental effect cytoreductive chemotherapy is superimposed on a developing immune system.
